Alluvi, formerly BI 4744, offers a notable breakthrough in weight management care. This dual stimulator targeting both GLP-1 and GIP targets demonstrates compelling effectiveness in research assessments, potentially https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/